Ingredient comparison

Orforglipron vs Semaglutide

Last updated

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Orforglipron vs Semaglutide: lowest prices now

  • Orforglipron: lowest FDA-approved

    LillyDirect (Eli Lilly)

    from $149/mo · about $149 per 30 days

  • Semaglutide: lowest FDA-approved

    NovoCare (Novo Nordisk)

    $149/30 days · about $149 per 30 days

  • Semaglutide: lowest compounded on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Every cash quote was checked on or after .Data feeds · Nov 16, 2026 UTC
Orforglipron vs Semaglutide: overview
CompareOrforglipronSemaglutide
What it is for

FDA-approved for

  • Weight loss

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver
Brands
Foundayo

Small-molecule GLP-1

Route & frequency

Oral tablet (any time of day, no food or water restriction)

Once daily

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill)

Once weekly (injectable); once daily (oral)

FDA shortage report

National reporting does not confirm stock at your pharmacy.

Coverage & source records

National reporting does not confirm stock at your pharmacy.

Coverage & source records
What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Orforglipron vs Semaglutide: sourced cash quotes
CompareOrforglipronSemaglutide
Advertised entry price
$149/30 days (pharmacy.amazon.com/FOUNDAYO-0-8-MG-TABLET-Bottle-30-Tablet/dp/B0GVPY57CT)

Foundayo via Amazon Pharmacy

Amazon Pharmacy

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy

Amazon Pharmacy

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

At the named trial dose
$299/30 days (pharmacy.amazon.com/Eli-Lilly-FOUNDAYO-17-2-MG-TABLET-Bottle-30-Tablet/dp/B0GVPWWC4K)

Foundayo via Amazon Pharmacy

At 17.2 mg

Amazon Pharmacy

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90)

30-day supply (pharmacy.amazon.com)

$299 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90)

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

$349/28 days (pharmacy.amazon.com/Novo-Nordisk-WEGOVY-2-4-MG-0-75-ML-PEN-INJECTOR-Box-3-Milliliter/dp/B09BHXXL2R)

Wegovy pen via Amazon Pharmacy

At 2.4 mg

Amazon Pharmacy

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

28-day supply (pharmacy.amazon.com)

≈ $373.93 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

Amazon fills a prescription you already have and delivers in all 50 states. Its $199 for 0.25 mg "Includes $100.00 off with manufacturer coupon if eligible": Novo Nordisk's coupon, which its terms limit to a new patient's first two 28-day fills, filled by Dec 31, 2026. FDA-approved product.

28-day supply

Every offerAll 51 offersAll 952 offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Orforglipron vs Semaglutide: individual trial outcomes
CompareOrforglipronSemaglutide
Weight change
−11.2% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose))

-11.2% at 72 wks

ATTAIN-1 (nejm.org)

17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)

Accounts for treatment discontinuation

Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

−14.9% (nejm.org/doi/full/10.1056/NEJMoa2032183) (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy))

-14.9% at 68 wks

STEP 1 (nejm.org)

2.4 mg weekly (Wegovy)

Accounts for treatment discontinuation

Study context

The headline is the standard 2.4 mg maintenance dose (Wegovy), the dose used in STEP 1 and one of the permitted doses in SURMOUNT-5. Other doses and formulations have their own trials, including STEP UP and OASIS 4. Their results are not interchangeable.

HbA1c change (percentage points)
−1.5 pp (investor.lilly.com/node/52521) (-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) · ACHIEVE-1 · HbA1c change in percentage points)

-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1)

ACHIEVE-1 (investor.lilly.com)
−1.6 pp (thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract) (-1.6% at 68 wks · STEP 2 · HbA1c change in percentage points)

-1.6 percentage points at 68 wks

STEP 2 (thelancet.com)
Adverse events

Stopped treatment for adverse events

10.3% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (10.3% vs 2.7% placebo (36 mg) · ATTAIN-1 (36 mg, 72 wks, obesity))

Reported nausea

33.7% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (Nausea in the drug arm · ATTAIN-1 (36 mg, 72 wks, obesity))

ATTAIN-1 (36 mg, 72 wks, obesity)

Stopped treatment for adverse events

7% (nejm.org/doi/full/10.1056/NEJMoa2032183) (7.0% vs 3.1% placebo · STEP 1 (2.4 mg, 68 wks, obesity))

Reported nausea

44.2% (nejm.org/doi/full/10.1056/NEJMoa2032183) (Nausea in the drug arm · STEP 1 (2.4 mg, 68 wks, obesity))

STEP 1 (2.4 mg, 68 wks, obesity)

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Foundayo17.2 mg from day 151about 29 to 49 hoursNoSep 26, 2037None listed

How long each takes · Generics and patents · Who covers what

Check the product label

Approved uses & full records

Orforglipron

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

53 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record

Semaglutide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

806 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Is Orforglipron or Semaglutide better for weight loss?

No trial on our list compared them directly. In separate trials: Orforglipron -11.2% at 72 wks in ATTAIN-1 (17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)) (nejm.org); Semaglutide -14.9% at 68 wks in STEP 1 (2.4 mg weekly (Wegovy)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.

Is Orforglipron or Semaglutide safer?

We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Orforglipron 10.3% vs 2.7% placebo (36 mg) (ATTAIN-1 (36 mg, 72 wks, obesity)) (nejm.org); Semaglutide 7.0% vs 3.1% placebo (STEP 1 (2.4 mg, 68 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.

What Semaglutide dose is equivalent to Orforglipron?

No FDA label sets a dose of Orforglipron that equals a dose of Semaglutide, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.

Which costs less: Orforglipron or Semaglutide?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Updated automatically

What changed for Orforglipron and Semaglutide

Written from each source's own record as it changes. Every change on GLPcompare

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.